Tel: (857) 239-0968 / (617) 419-7131
Home > RET
Cat.No. Product Name Information Area
T2288 Motesanib Motesanib is an orally bioavailable receptor tyrosine kinase inhibitor with potential... Cancer
T3065 TG101209 TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM, less potent to Flt3 and RET... Cancer
T2639 LY2811376 LY2811376 is the first orally available non-peptidic β-secretase(BACE1) inhibitor wit... Nervous system
T2620 G-749 G-749 is a novel and potent FLT3 inhibitor with IC50 of 0.4 nM, 0.6 nM and 1 nM for F... Cardiovascular System
T2582 Apatinib Apatinib is an orally bioavailable, selective VEGFR2 inhibitor with IC50 of 1 nM. Cancer
T2358 ENMD-2076 ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.8... Cancer
T2288L Motesanib Diphosphate (AMG-706) Motesanib Diphosphate (AMG-706) is a potent ATP-competitive inhibitor of VEGFR1/2/3 w... Cancer
T2282 RPI-1 RPI-1 reduced the phosphorylation of RET, MET, DCDB2, CTND1, and PLCγ。 Cancer
T2094 Danusertib Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 1... Cancer
T2070 CEP-32496 CEP-32496 is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/3... Other
T1995 Fedratinib (SAR302503, TG101348) Fedratinib (SAR302503, TG101348) is a selective inhibitor of JAK2 with IC50 of 3 nM i... Other
T0093 Sorafenib tosylate Sorafenib tosylate (BAY 43-9006) is a potent inhibitor of Raf-1 with IC50 values of 6... Cancer